Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1706-1713

  Bruce, Ian N ^a,b   O'Keeffe, Aidan G ^c   Farewell, Vern ^d   Hanly, John G ^e   Manzi, Susan ^f   Su, Li ^d   Gladman, Dafna D ^g   Bae, Sang Cheol ^h   Sanchez Guerrero, Jorge ^g   Romero Diaz, Juanita ⁱ   Gordon, Caroline ^j   Wallace, Daniel J ^k   Clarke, Ann E ^l   Bernatsky, Sasha ^m   Ginzler, Ellen M ⁿ   Isenberg, David A ^c   Rahman, Anisur ^c   Merrill, Joan T ^o   Alarcón, Graciela S ^p   Fessler, Barri J ^p   Fortin, Paul R ^q   Petri, Michelle ^r   Steinsson, Kristjan ^s   Dooley, Mary Anne ^t   Khamashta, Munther A ^u   Ramsey Goldman, Rosalind ^v   Zoma, Asad A ^w   Sturfelt, Gunnar K ^x   Nived, Ola ^x   Aranow, Cynthia ^y   Mackay, Meggan ^y   Ramos Casals, Manuel ^z   Van Vollenhoven, Ronald F ^aa   Kalunian, Kenneth C ^ab   Ruiz Irastorza, Guillermo ^ac   Lim, Sam ^ad   Kamen, Diane L ^ae   Peschken, Christine A ^af   Inanc, Murat ^ag   Urowitz, Murray B ^g   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MRC BIOSTATISTICS UNIT   (United Kingdom)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f ALLEGHENY HEALTH NETWORK   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h Hanyang University Hospital for Rheumatic Diseases   (South Korea)

ⁱ INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALGARY   (Canada)

^m MONTREAL GENERAL HOSPITAL   (Canada)

ⁿ Downstate Health Sciences University   (United States)

^o OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^p University of Alabama at Birmingham   (United States)

^q LAVAL UNIVERSITY   (Canada)

^r JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^t UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^u ST THOMAS HOSPITAL   (United Kingdom)

^v NORTHWESTERN UNIVERSITY   (United States)

^w HAIRMYRES HOSPITAL   (United Kingdom)

^x LUND UNIVERSITY HOSPITAL   (Sweden)

^y FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^z HOSPITAL CLÍNIC   (Spain)

^aa KAROLINSKA INSTITUTE   (Sweden)

^ab UNIVERSITY OF CALIFORNIA   (United States)

^ac BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^ad EMORY UNIVERSITY   (United States)

^ae MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^af UNIVERSITY OF MANITOBA   (Canada)

^ag ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ETHNICITY; FEMALE; GEOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SCORING SYSTEM; SEROLOGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ETHNIC GROUP; HEALTH STATUS; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; ETHNIC GROUPS; FEMALE; HEALTH STATUS; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; YOUNG ADULT;

EID: 84924190291     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205171     Document Type: Article

References (27)

1. Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
2. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
3. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
4. Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013;43:352-61.
5. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
6. Nived O, Jonsen A, Bengtsson AA, et al. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002;29:1398-400.
7. Cardoso CR, Signorelli FV, Papi JA, et al. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus 2008;17:1042-8.
8. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
9. Alarcon GS, Roseman JM, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004;43:202-5.
10. Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009;48:673-5.
11. Maddison P, Farewell V, Isenberg D, et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 2002;29:913-17.
12. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7.
13. Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998;25:654-9.
14. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
15. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology 2004;43:1039-44.
16. Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009;38:121-7.
17. Prasad R, Ibanez D, Gladman D, et al. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 2006;15:285-91.
18. Fessler BJ, Alarcon GS, McGwin G Jr., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
20. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
21. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
22. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008;58:843-53.
23. Cassano G, Roverano S, Paira S, et al. Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study. Clin Rheumatol 2007;26:2017-22.
24. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004;13:900-5.
25. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
26. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. Arthritis Rheum 2008;58:4029-30.
27. Sundaramurthy S, Bush TM, Neuwelt CM, et al. Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus. Lupus 2003;12:443-8.